DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES (Q2035396)

From EU Knowledge Graph
Revision as of 08:42, 2 November 2020 by DG Regio (talk | contribs) (‎Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement)
Jump to navigation Jump to search
Project Q2035396 in Italy
Language Label Description Also known as
English
DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES
Project Q2035396 in Italy

    Statements

    0 references
    5,714.0 Euro
    0 references
    11,428.0 Euro
    0 references
    50.0 percent
    0 references
    15 November 2016
    0 references
    7 December 2018
    0 references
    3 December 2018
    0 references
    TAKIS SRL
    0 references
    0 references
    0 references

    41°53'35.95"N, 12°28'58.55"E
    0 references
    L'AZIENDA DI BIOTECNOLOGIE TAKIS PRODUCE IN MODO INNOVATIVO ED EFFICACE ANTICORPI MONOCLONALI PER CONTO PROPRIO E PER CONTO TERZI. SEBBENE MOLTO COMPETITIVA NEI PROTOCOLLI DI VACCINAZIONE, IL PROCESSO ATTUALE MANCA DI UN SISTEMA ROBOTIZZATO PER L (Italian)
    0 references
    THE BIOTECH COMPANY IS INNOVATIVE AND EFFECTIVE MONOCLONAL ANTIBODIES FOR OWN ACCOUNT AND FOR HIRE OR REWARD. ALTHOUGH HIGHLY COMPETITIVE IN VACCINATION PROTOCOLS, THE CURRENT PROCESS LACKS A ROBOTIC SYSTEM FOR (English)
    0 references

    Identifiers

    F83G17000640007
    0 references